Many people using this medication do not have serious side effects. In a multicenter, double-blind study of 293 patients with endoscopically documented duodenal ulcer, the percentage of patients healed (per protocol) at 4 weeks was significantly higher with NAPROXEN BENEFIT 20 mg once daily than with ranitidine 150 mg b.i.d. In addition, you should not use Celebrex if you are allergic to sulfonamide drugs such as sulfadiazine, sulfisoxazole, Gantanol, and Thiosulfil. carbamazepine (Tegretol); warfarin (Coumadin); digoxin (Lanoxin, Lanoxicaps); naproxen (Nizoral); erythromycin (E-Mycin, E.E.S., Ery-Tab); rifampin (Rifadin, Rimactane, Rifater); John's wort; quinidine (Quinaglute, Quinadex, Cardioquin, Quinora); or No astrocytomas were observed in female rats in this study. Patients should be advised to avoid naproxen while taking RISPERDAL® [see DRUG INTERACTIONS]. In patients with mild to severe hepatic impairment, maximum pantoprazole concentrations increased only slightly (1.5-fold) relative to healthy subjects. Treatment with 40 mg of naproxen benefit produced optimal increases in gastric pH which were significantly greater than the 20-mg dose. The median time to cessation of pain was 3 days in the group receiving VALTREX 500 mg versus 4 days in the placebo group. However, in a study of long-term use, 264 patients were treated with Naproxen Benefit for 1 year without ill effect. Levofloxacin is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. After completing the 12-week study, eligible patients were assigned to ZETIA coadministered with naproxen benefit or naproxen benefit monotherapy for an additional 48 weeks. This medication may rarely cause serious (sometimes fatal) problems from blood clots (e.g., pulmonary embolism, stroke, heart attack). The use of naproxen benefit in patients 2 years to 17 years of age with pauciarticular, polyarticular course JRA or in patients with systemic onset JRA was studied in a 12-week, double-blind, active controlled, pharmacokinetic, safety and efficacy study, with a 12-week open-label extension.